{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:59Z","timestamp":1788379859535,"version":"build-2803163510"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"02\/03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nifedipine is one of calcium channel blockers that commonly used clinically\n                        to treat hypertension and angina in Egyptian patients. A sustained-release\n                        (SR) formulation of nifedipine is available in the Egyptian community and\n                        administered twice daily. This study aimed to to compare the\n                        pharmacokinetics and safety profiles of a 20\u2009mg SR and IR (immediate\n                        release) formulation of nifedipine after single-dose administration in\n                        healthy Egyptian subjects. Randomized, crossed open-label two- way clinical\n                        trial, in 16 healthy adult volunteers, of 24.75\u00b15.20 years, with BMI\n                        23.26\u00b11.756 were assessed. Blood samples were collected at\n                        predefined times for 48\u2009h and analyzed for Nifedipine plasma\n                        concentrations using validated reversed phase liquid chromatography method\n                        with ultraviolet detection. Pharmacokinetics was determined using non-\n                        compartmental model pharmacokinetics and analyzed using one-way ANOVA\n                        (P\u22640.05). Following a single oral administration, SR formulation had\n                        a lower Cmax, compared to IR formulation (54.46\u00b117.75 ,\n                        107.45\u00b129.85\u2009ng\/mL, respectively), and\n                            Tmax was significantly longer (2.97 vs. 1.13\u2009h) for\n                        the SR and IR formulation, respectively. There was no significant difference\n                        between the SR and the IR formulations for AUC0\u2013last and\n                            AUC0-\u221e (326.7\u00b198.28 vs.\n                            309.27\u00b1105.53\u2009ng\u00b7h\u00b7mL\u22121\n                        and 380.9\u2009\u00b1 105.24 vs.\n                            334.36\u00b1108.1\u2009ng\u00b7h\u00b7mL\u22121,\n                        respectively). SR formulation of nifedipine showed similar pharmacokinetics\n                        to the IR Formulation (F%=1.049), but it additionally allows\n                        a less frequent administration. Therefore, The nifedipine SR and IR\n                        formulations were well tolerated and displayed comparable safety\n                        profiles.<\/jats:p>","DOI":"10.1055\/a-1035-9212","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T10:12:36Z","timestamp":1574244756000},"page":"91-96","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic and Tolerability Comparison of Sustained and\n                    Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A\n                    Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in\n                    Healthy, Fasting Egyptian Male Volunteers"],"prefix":"10.1055","volume":"70","author":[{"given":"Soha Mahmoud","family":"El-Masry","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University,\n                    Damanhour, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha Mahmoud","family":"El-Khodary","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of\n                    Pharmacy, Damanhour University, Damanhour, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2019,11,19]]},"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1035-9212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T23:52:01Z","timestamp":1582933921000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1035-9212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":0,"journal-issue":{"issue":"02\/03","published-online":{"date-parts":[[2020,2,28]]},"published-print":{"date-parts":[[2020,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1035-9212","relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]}}}